BIOTECH EXPERIENCE

DRUG DEVELOPMENT EXPERIENCE FOR BIOTECHS

Comprehensive Experience Across More Than 120 Therapeutic Indications.

Over the past three decades Avance Clinical has been at the forefront of biotech clinical research across more than 120 therapeutic indications. The experience gained over these years guides and informs client decision-making at every stage to maximize the success of clinical research and achievement of trial outcomes.

While Avance Clinical has built up a wealth of knowledge, relationships with sites and specialists, and patient advocacy groups across these therapeutic areas it also has a strong focus on Cell & Gene Therapies, Central Nervous System (CNS), Dermatology, Endocrinology, Infectious Diseases, Oncology, Ophthalmology, Rare Disease & Orphan Drug, and Respiratory & Allergy indications.

BIOTECH Specialists

Avance Clinical has specialist gene technology accreditation (Office of Gene Technology Regulator [OGTR] in Australia) and is experienced in managing cell and gene therapy trials globally for its biotech clients.

The clinical operations, project management, and scientific and regulatory affairs teams offer decades of deep clinical research management experience across Australia, New Zealand, Asia, North America, and Europe.

CONTACT OUR IN HOUSE SCIENTIFIC & REGULATORY AFFAIRS TEAM
IN AUSTRALIA, NORTH AMERICA AND EUROPE

Delivering more than 30 years experience of drug development expertise

OUR AREAS OF
EXPERTISE AND EXPERIENCE

Central nervous system

Dermatology

Endocrinology

Haematology

Hepatology

Immunology

Infectious diseases

Metabolism & nutritional disorders

Oncology

Ophthalmology

Otorhinolaryngology (ENT)

Rare & orphan indications

Respiratory, allergy, thoracic & mediastinal disorders

Sexual dysfunction & disorders

Urology

WHY BIOTECHS CHOOSE
AVANCE CLINICAL

More than three decades of deep clinical research management experience, Avance Clinical is the largest
specialist Australian and US CRO delivering quality clinical trials in Australia, New Zealand, Asia and North America for international biotechs.

43.5%

REBATE

5-6 Wks

START-UP TIME

100%

CAPABILITIES

FDA

COMPLIANT RESEARCH